Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment

Overview

Journal Acta Derm Venereol

Specialty Dermatology

Date 2020 Jun 20

PMID 32556359

Citations 7

Authors

Sonja Grundel

Manuel P Pereira

Michael Storck

Nani Osada

Gudrun Schneider

Sonja Stander

Claudia Zeidler

Affiliations

Soon will be listed here.

Abstract

Chronic nodular prurigo presents with multiple pruriginous nodules and severe pruritus. This study aims to explore the treatment course and regimens in patients with chronic nodular prurigo and to analyse predictive factors contributing to therapeutic success. A total of 325 patients with chronic nodular prurigo (male 37.5%) were analysed concerning demographic data, pruritus intensity, medical history, psychological impairment, quality of life, treatment duration, regimens and outcome. These parameters were compared with 325 sex- and age-matched patients with chronic pruritus on non-lesional skin. Treatment success was dependent on duration and regime of treatment and independent of age, sex and initial itch intensity. Non-responders displayed a higher percentage of inflamed nodules, a higher portion of excoriated nodules and a higher impairment of quality of life and mood factors before initiation of treatment. Gabapentinoids and immunosuppressants proved to be the most successful therapeutic agents. Compared with patients with chronic pruritus, those with chronic nodular prurigo needed longer duration of therapy.

Citing Articles

The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.

Erdem Y, Ntousounous O, Ozkaya E Sisli Etfal Hastan Tıp Bul. 2025; 58(4):477-482.

PMID: 39816422 PMC: 11729828. DOI: 10.14744/SEMB.2024.46144.

[Treatment of chronic prurigo: update and perspectives].

Witte F, Stander S, Zeidler C Dermatologie (Heidelb). 2024; 75(8):623-628.

PMID: 38869847 DOI: 10.1007/s00105-024-05375-y.

Prurigo nodularis: new insights into pathogenesis and novel therapeutics.

Liao V, Cornman H, Ma E, Kwatra S Br J Dermatol. 2024; 190(6):798-810.

PMID: 38345154 PMC: 11099982. DOI: 10.1093/bjd/ljae052.

Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.

Taghaddos D, Savinova I, Abu-Hilal M J Cutan Med Surg. 2024; 28(2):141-145.

PMID: 38281092 PMC: 11015701. DOI: 10.1177/12034754241227808.

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.

Muller S, Zeidler C, Stander S Am J Clin Dermatol. 2023; 25(1):15-33.

PMID: 37717255 PMC: 10796623. DOI: 10.1007/s40257-023-00818-z.

References

Pereira M, Basta S, Moore J, Stander S . Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. J Eur Acad Dermatol Venereol. 2018; 32(12):2224-2229. PMC: 6585684. DOI: 10.1111/jdv.15107. View

Kabashima K, Furue M, Hanifin J, Pulka G, Wollenberg A, Galus R . Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018; 142(4):1121-1130.e7. DOI: 10.1016/j.jaci.2018.03.018. View

Stander S, Blome C, Anastasiadou Z, Zeidler C, Jung K, Tsianakas A . Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus. Acta Derm Venereol. 2016; 97(2):230-234. DOI: 10.2340/00015555-2494. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Matsuda K, Sharma D, Schonfeld A, Kwatra S . Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol. 2016; 75(3):619-625.e6. DOI: 10.1016/j.jaad.2016.02.1237. View

Bjelland I, Dahl A, Haug T, Neckelmann D . The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002; 52(2):69-77. DOI: 10.1016/s0022-3999(01)00296-3. View

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

Pereira M, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M . European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2017; 32(7):1059-1065. DOI: 10.1111/jdv.14570. View

Rinaldi G . The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol Pract Concept. 2019; 9(2):90-97. PMC: 6502296. DOI: 10.5826/dpc.0902a03. View

10.

Zeidler C, Pereira M, Stander S . The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo. Dermatol Ther (Heidelb). 2019; 9(4):613-622. PMC: 6828989. DOI: 10.1007/s13555-019-00321-6. View

11.

Wallengren J . Prurigo: diagnosis and management. Am J Clin Dermatol. 2004; 5(2):85-95. DOI: 10.2165/00128071-200405020-00003. View

12.

Stander S, Blome C, Breil B, Bruland P, Darsow U, Dugas M . [Assessment of pruritus - current standards and implications for clinical practice : consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP)]. Hautarzt. 2012; 63(7):521-2, 524-31. DOI: 10.1007/s00105-011-2318-3. View

13.

Pereira M, Nau T, Zeidler C, Stander S . [Chronic prurigo]. Hautarzt. 2018; 69(4):321-330. DOI: 10.1007/s00105-018-4145-2. View

14.

Zeidler C, Tsianakas A, Pereira M, Stander H, Yosipovitch G, Stander S . Chronic Prurigo of Nodular Type: A Review. Acta Derm Venereol. 2017; 98(2):173-179. DOI: 10.2340/00015555-2774. View

15.

Reich A, Szepietowski J . Measurement of Itch Intensity. Curr Probl Dermatol. 2016; 50:29-34. DOI: 10.1159/000446014. View

16.

Weisshaar E, Szepietowski J, Dalgard F, Garcovich S, Gieler U, Gimenez-Arnau A . European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019; 99(5):469-506. DOI: 10.2340/00015555-3164. View

17.

Schneider G, Grebe A, Bruland P, Heuft G, Stander S . Chronic pruritus patients with psychiatric and psychosomatic comorbidity are highly burdened: a longitudinal study. J Eur Acad Dermatol Venereol. 2019; 33(8):e288-e291. DOI: 10.1111/jdv.15559. View

18.

Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M . Psychological factors involved in prurigo nodularis: A pilot study. J Dermatolog Treat. 2010; 22(4):211-4. DOI: 10.3109/09546631003674321. View

19.

Qureshi A, Abate L, Yosipovitch G, Friedman A . A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2018; 80(3):756-764. DOI: 10.1016/j.jaad.2018.09.020. View

20.

Apfelbacher C, van Zuuren E, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E . Oral H1 antihistamines as monotherapy for eczema. Cochrane Database Syst Rev. 2013; (2):CD007770. PMC: 6823266. DOI: 10.1002/14651858.CD007770.pub2. View